Predictive markers in breast cancer – the present
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Breast cancer is a heterogeneous disease and there is a continual drive to identify markers that will aid in predicting prognosis and response to therapy. To date, relatively few markers have established prognostic power. Oestrogen receptor (ER) is probably the most powerful predictive marker in breast cancer management, both in determining prognosis and in predicting response to hormone therapies. Progesterone receptor (PR) is also a widely used marker, although its value is less well established. HER‐2 status has also become a routine prognostic and predictive factor in breast cancer. Given the importance of these biological markers in patient management, it is essential that assays are robust and quality controlled, and that interpretation is standardized. Furthermore, it is important to be aware of the limitations in their predictive power, and how this may be refined through addition of further biological markers. The aim of this review is to provide an overview of the established role of ER, PR and HER‐2 in patient management, the current standards for assessing these markers, as well as highlighting the controversies that still surround their use and methods of assessment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“Amplification is the predominant mechanism of gene overexpression and abnormally high levels of the 185-kDa glycoprotein are seen in approximately 18–20% of breast cancers.(23) HER-2 positivity is associated with highgrade tumours, lymph node involvement,(24) a higher rate of disease recurrence and mortality, and thus…”
BackgroundSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“This is a humanized monoclonal antibody, which has been shown in several studies to improve response rates, time to progression and overall survival, either alone or in combination with chemotherapy, in patients with metastatic breast cancer.(26) More recently, five international prospective randomized clinical trials…”
Background
Cited by
Targeting HER2-positive breast cancer: advances and future directions
Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160
A pan-cancer proteomic perspective on The Cancer Genome Atlas
Akbani, R., Ng, P. K. S., Werner, H. M. J., Shahmoradgoli, M., Zhang, F., Ju, Z., Liu, W., Yang, J.-Y., Yoshihara, K., Li, J., et al. (2014) · Nature Communications · doi:10.1038/ncomms4887 · Cited by 607
Breast Cancer: Current Perspectives on the Disease Status
Fahad Ullah, M. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-20301-6_4 · Cited by 598
Histological, molecular and functional subtypes of breast cancers
Malhotra, G. K., Zhao, X., Band, H., & Band, V. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.10.13879 · Cited by 475
New prognostic factors and scoring system for patients with skeletal metastasis
Katagiri, H., Okada, R., Takagi, T., Takahashi, M., Murata, H., Harada, H., Nishimura, T., Asakura, H., & Ogawa, H. (2014) · Cancer Medicine · doi:10.1002/cam4.292 · Cited by 421
Metadata
- Authors
- Payne, S. J. L., Bowen, R. L., Jones, J. L., & Wells, C. A.
- Venue
- Histopathology
- Publisher
- Wiley
- Published
- 2007-12-13
- Volume
- 52
- Issue
- 1
- Pages
- 82-90
- ISSN
- 0309-0167 (ISSN-L)
- 1365-2559
- OpenAlex
- W1860205630
- Cited by
- 229
- References
- 2
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.